证券代码：688580 证券简称：伟思医疗 公告编号：2025-037 南京伟思医疗科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 9 月 15 日 （二） 股东大会召开的地点：南京市雨花台区宁双路 19 号 H 栋公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 39 | | --- | --- | | 普通股股东人数 | 39 | | 2、出席会议的股东所持有的表决权数量 | 62,083,029 | | 普通股股东所持有表决权数量 | 62,083,029 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 64.8646 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 64.8646 | 注：截至本次股东大会 ...

伟思医疗 2025年第一次临时股东大会 南京伟思医疗科技股份有限公司: 根据《中华人民共和国公司法》(以下简称"《公司法》")《中华人民共和国 证券法》(以下简称"《证券法》")和中国证监会发布的《上市公司股东会规则》 等法律、法规和规范性文件以及《南京伟思医疗科技股份有限公司章程》(以下 简称"《公司章程》")的规定,本所受公司的委托,指派本所律师出席公司 2025 年第一次临时股东大会,并就本次股东大会的召集、召开程序、出席会议人员资 格、召集人资格、表决程序以及表决结果的合法有效性等事项出具法律意见。 为出具本法律意见书,本所律师对本次股东大会所涉及的有关事项进行了审 查,查阅了相关会议文件,并对有关问题进行了必要的核查和验证。 本所律师同意将本法律意见书随公司本次股东大会决议一并公告,并依法对 本法律意见书承担相应的责任。 本所律师根据相关法律、法规和规范性文件的要求,按照律师行业公认的业 务标准、道德规范和勤勉尽责精神,出具法律意见如下: 一、关于本次股东大会的召集、召开程序 1.本次股东大会的召集 本次股东大会由董事会召集。2025年8月27日,公司召开了第四届董事会 第五次会议,决定于 2025 ...

Core Viewpoint - The company has a strong presence in the non-invasive brain-computer interface (BCI) field, with a comprehensive range of products and technologies, including group biofeedback, multi-parameter biofeedback, and neonatal EEG monitoring [1] Group 1: Product and Technology Development - The company has obtained dozens of patents related to brain-computer interfaces, covering core technologies such as EEG signal acquisition, interference signal correction, signal transmission analysis, and machine learning algorithms [1] - The company has also accumulated multiple patents and technological reserves in non-invasive BCI electrodes [1] Group 2: Neurological Rehabilitation Solutions - The company's technology layout in the neurological rehabilitation field has evolved from a single device to a full-cycle solution encompassing "diagnosis-treatment-rehabilitation" [1] - For closed-loop neurological rehabilitation systems, the company has developed technologies for EEG acquisition, non-invasive neural modulation, and rehabilitation robots, enabling a closed-loop rehabilitation chain that includes brain signal acquisition, intention analysis, magnetic stimulation modulation, and mechanical assistance execution [1] Group 3: Clinical Applications - For stroke patients, the company can capture motor imagery signals in real-time using EEG caps, triggering rehabilitation robots for training while utilizing transcranial magnetic stimulation (TMS) to enhance neural plasticity and accelerate motor function recovery [1] - For spinal cord injury patients, the company's surface electromyography analysis system can assess residual nerve function, combined with a pulsed magnetic field therapy device to intervene in damaged spinal segments, creating personalized rehabilitation plans [1] Group 4: Future Directions - The company will closely monitor the development and application of cutting-edge neuroscience technologies, actively exploring various forms of business and technical cooperation to promote the transition of rehabilitation medicine from traditional models to precision and intelligent development [1]

Core Viewpoint - The company has a strong presence in the non-invasive brain-computer interface (BCI) field, with a comprehensive range of products and technologies, including group biofeedback, multi-parameter biofeedback, and neonatal EEG monitoring [1] Group 1: Product and Technology Development - The company has obtained dozens of patents related to brain-computer interfaces, covering core technologies such as EEG signal acquisition, interference signal correction, signal transmission analysis, and machine learning algorithms [1] - The company has also accumulated multiple patents and technological reserves in non-invasive BCI electrodes [1] Group 2: Neurological Rehabilitation Solutions - The company's technology layout in the neurological rehabilitation field has evolved from a single device to a full-cycle solution encompassing "diagnosis-treatment-rehabilitation" [1] - For closed-loop neurological rehabilitation systems, the company has developed technologies for EEG acquisition, non-invasive neural modulation, and rehabilitation robots, enabling a closed-loop rehabilitation chain that includes brain signal acquisition, intention analysis, magnetic stimulation regulation, and mechanical assistance execution [1] Group 3: Clinical Applications - For stroke patients, the company can capture motor imagery signals in real-time using EEG caps, triggering rehabilitation robots for training while utilizing transcranial magnetic stimulation (TMS) to enhance neural plasticity and accelerate motor function recovery [1] - For spinal cord injury patients, the company's surface electromyography analysis system can assess residual nerve function, combined with a pulsed magnetic field therapy device to intervene in damaged spinal segments, creating personalized rehabilitation plans [1] Group 4: Future Directions - The company will closely monitor the development and application of cutting-edge neuroscience technologies, actively exploring various forms of business and technical cooperation to promote the transition of rehabilitation medicine from traditional models to precision and intelligent development [1]

北信瑞丰健康生活主题灵活配置（001056）基金经理为庞文杰。 资料显示，南京伟思医疗科技股份有限公司位于江苏省南京市雨花台区宁双路19号9栋，成立日期2001 年1月10日，上市日期2020年7月21日，公司主营业务涉及康复医疗器械的研发、生产和销售,以研发创 新为发展驱动力,致力于在盆底及产后康复、神经康复、精神康复等细分领域为医疗及专业机构提供安 全、有效的康复医疗产品及整体解决方案。主营业务收入构成为：磁刺激类39.44%，耗材及配件 19.42%，电生理类19.18%，激光射频类10.26%，电刺激类8.42%，其他3.28%。 从基金十大重仓股角度 数据显示，北信瑞丰基金旗下1只基金重仓伟思医疗。北信瑞丰健康生活主题灵活配置（001056）二季 度减持4万股，持有股数9万股，占基金净值比例为4.68%，位居第七大重仓股。根据测算，今日浮亏损 失约24.3万元。 北信瑞丰健康生活主题灵活配置（001056）成立日期2015年3月27日，最新规模8937.79万。今年以来收 益38.97%，同类排名1228/8179；近一年收益76.4%，同类排名927/7984；成立以来收益32.3%。 9月9日， ...

Group 1 - The core viewpoint of the news is the performance and market position of Weisi Medical, which saw a stock price increase of 5.02% to 54.19 CNY per share, with a total market capitalization of 5.19 billion CNY [1] - Weisi Medical specializes in the research, production, and sales of rehabilitation medical devices, focusing on areas such as pelvic and postpartum rehabilitation, neurological rehabilitation, and mental rehabilitation [1] - The company's revenue composition includes magnetic stimulation products (39.44%), consumables and accessories (19.42%), electrophysiological products (19.18%), laser radiofrequency products (10.26%), electrical stimulation products (8.42%), and others (3.28%) [1] Group 2 - From the perspective of fund holdings, Weisi Medical is a significant investment for the Beixin Ruifeng Health Life Theme Flexible Allocation Fund, which reduced its holdings by 40,000 shares but still holds 90,000 shares, representing 4.68% of the fund's net value [2] - The Beixin Ruifeng Health Life Theme Flexible Allocation Fund has achieved a year-to-date return of 33.09% and a one-year return of 63.27%, ranking 1803 out of 8248 and 1504 out of 8051 in its category, respectively [2] - The fund manager, Pang Wenjie, has a tenure of over 5 years, with the best fund return during this period being 44.46% and the worst being -39.77% [3]

南京伟思医疗科技股份有限公司 2025 年第一次临时股东大会会议资料 证券代码：688580 证券简称：伟思医疗 南京伟思医疗科技股份有限公司 2025年第一次临时股东大会会议资料 2025 年 9 月 南京伟思医疗科技股份有限公司 2025 年第一次临时股东大会会议资料 2025 年第一次临时股东大会会议资料目录 | 2025 年第一次临时股东大会会议资料目录 1 | | | --- | --- | | 2025 年第一次临时股东大会会议须知 1 | | | 2025 年第一次临时股东大会会议议程 4 | | | 议案 1： 6 | | | 《关于取消监事会、修订<公司章程>并办理工商变更登记的议案》 | 6 | | 议案 2： 8 | | | 《关于补选公司第四届董事会独立董事候选人的议案》 | 8 | | 议案 3： 10 | | | 《关于修订部分公司内部治理制度的议案》 | 10 | 南京伟思医疗科技股份有限公司 2025 年第一次临时股东大会会议资料 2025 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司 ...

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook based on revenue growth and profitability improvements [1][2]. Core Insights - The company reported a revenue of 210 million yuan for the first half of 2025, representing a year-over-year increase of 9.85%, with a net profit of 69 million yuan, up 39.71% year-over-year [1][2]. - The revenue growth is attributed to a gradual recovery in market demand and successful promotion of new products, particularly in the magnetic stimulation and consumables segments [2]. - The company has a strong competitive position in the magnetic stimulation market, with expectations for growth as new products like MagNeuro ONE are launched [2]. - The profitability has significantly improved, with a net profit margin of 32.94% in the first half of 2025, benefiting from reduced costs and improved efficiency [2]. - The company is expanding into the medical aesthetics sector, with new products expected to drive future growth [2]. - The integration of AI and brain-machine interface technologies is anticipated to enhance product performance and competitiveness [2]. Financial Summary - For 2025, the company is projected to achieve revenues of 474 million yuan, with a year-over-year growth rate of 18.5%, and a net profit of 139 million yuan, reflecting a growth rate of 36.2% [3]. - The gross margin is expected to be around 66.7% in 2025, with a return on equity (ROE) of 8.4% [3]. - The earnings per share (EPS) is projected to be 1.45 yuan in 2025, with a price-to-earnings (P/E) ratio of approximately 35.58 [3].

Group 1: Company Insights - E Fund recently conducted research on seven listed companies, highlighting significant growth in revenue for Yuanjie Technology, particularly in the demand for 400G/800G optical modules, with expectations for substantial growth in the second half of 2025 [1] - Weisi Medical's lower limb exoskeleton device has been included in the medical insurance directory, and its electrical stimulation products are primarily used in obstetrics and gynecology departments [1] - Dekoli experienced rapid growth in computing power demand but faced challenges with capacity and supply chain resources, leading to insufficient order fulfillment [1] - Ningbo Jingda's performance was slightly impacted by international trade factors, but it saw a double-digit growth in orders in the second quarter, with a 70% increase in export orders after acquiring Wuxi Micro Research [2] - Xinmai Medical reported a revenue of 714 million yuan and a net profit of 315 million yuan, with overseas revenue growing over 95% [3] - Kehua Data achieved a revenue of 3.733 billion yuan, with a 0.06% year-on-year growth, and a 16.77% increase in data center business revenue [4] Group 2: Industry Trends - The demand for high-power CW light sources and high-speed EML technology is increasing, with companies focusing on core technology breakthroughs and maintaining high gross profit margins [1] - The integration of advanced technologies in manufacturing, such as high-frequency pipe-making and rolling machines, is being pursued to promote import substitution in the industry [2] - The development of new energy solutions, including 2000V450kW inverters, is being accelerated to serve various sectors, including state-owned enterprises [3] - The semiconductor industry is facing challenges with high R&D investments and increased financial costs, impacting profitability for companies like Dongxin [5]

Group 1: Company Insights - Weis Medical's lower limb exoskeleton device has been included in the medical insurance directory, and its electrical stimulation products are primarily used in obstetrics and gynecology departments [1] - Dongfang Shenghong's refining segment achieved a net profit of 257 million yuan in the first half of 2025, turning a profit compared to the previous year, with plans for further capital expenditure reduction as new projects come online [1] - Dekoli is experiencing rapid growth in computing power demand, but faces challenges in capacity and supply chain resources, with a projected improvement expected in the second half of the year as a new factory comes online [2] - Guangdong Hongtu reported a revenue of 4.27 billion yuan in the first half of the year, a year-on-year increase of 17.21%, but a net profit decline of 34.08% due to rising raw material costs and increased competition [2] Group 2: Industry Trends - The refining and chemical industry is expected to benefit from anti-involution policies, with Dongfang Shenghong positioned as a scalable integrated refining enterprise [1] - The telecommunications sector is facing a decline, with Dekoli reporting an 8% year-on-year decrease in telecom business revenue [2] - The market is gradually increasing in concentration, with Guangdong Hongtu aiming to strengthen its core businesses while exploring new opportunities in low-altitude economy and intelligent robotics [2] Group 3: Fund Performance - Debang Fund, established in 2012, has an asset management scale of 54.524 billion yuan, ranking 83rd among 210 funds, with a notable performance from its best fund, which saw a growth of 222.91% in the past year [3]